Logo image of TLRY.CA

TILRAY BRANDS INC (TLRY.CA) Stock Fundamental Analysis

TSX:TLRY - Toronto Stock Exchange - US88688T1007 - Common Stock - Currency: CAD

0.56  0 (0%)

Fundamental Rating

2

Taking everything into account, TLRY scores 2 out of 10 in our fundamental rating. TLRY was compared to 34 industry peers in the Pharmaceuticals industry. The financial health of TLRY is average, but there are quite some concerns on its profitability. While showing a medium growth rate, TLRY is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TLRY had negative earnings in the past year.
In the past year TLRY has reported a negative cash flow from operations.
TLRY had negative earnings in each of the past 5 years.
In the past 5 years TLRY reported 4 times negative operating cash flow.
TLRY.CA Yearly Net Income VS EBIT VS OCF VS FCFTLRY.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B

1.2 Ratios

With a Return On Assets value of -27.79%, TLRY is not doing good in the industry: 74.29% of the companies in the same industry are doing better.
TLRY has a Return On Equity of -34.64%. This is in the lower half of the industry: TLRY underperforms 62.86% of its industry peers.
Industry RankSector Rank
ROA -27.79%
ROE -34.64%
ROIC N/A
ROA(3y)-16.09%
ROA(5y)-22.56%
ROE(3y)-20.59%
ROE(5y)-49.37%
ROIC(3y)N/A
ROIC(5y)N/A
TLRY.CA Yearly ROA, ROE, ROICTLRY.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

With a Gross Margin value of 30.88%, TLRY perfoms like the industry average, outperforming 54.29% of the companies in the same industry.
TLRY's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for TLRY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 30.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34.12%
GM growth 5Y-3.12%
TLRY.CA Yearly Profit, Operating, Gross MarginsTLRY.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

More info and screens

4

2. Health

2.1 Basic Checks

TLRY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TLRY has been increased compared to 1 year ago.
Compared to 5 years ago, TLRY has more shares outstanding
The debt/assets ratio for TLRY has been reduced compared to a year ago.
TLRY.CA Yearly Shares OutstandingTLRY.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
TLRY.CA Yearly Total Debt VS Total AssetsTLRY.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.2 Solvency

TLRY has an Altman-Z score of -0.81. This is a bad value and indicates that TLRY is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.81, TLRY is in line with its industry, outperforming 48.57% of the companies in the same industry.
TLRY has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of TLRY (0.11) is better than 62.86% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z -0.81
ROIC/WACCN/A
WACC8.83%
TLRY.CA Yearly LT Debt VS Equity VS FCFTLRY.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

2.3 Liquidity

A Current Ratio of 2.62 indicates that TLRY has no problem at all paying its short term obligations.
TLRY's Current ratio of 2.62 is fine compared to the rest of the industry. TLRY outperforms 68.57% of its industry peers.
A Quick Ratio of 1.61 indicates that TLRY should not have too much problems paying its short term obligations.
TLRY's Quick ratio of 1.61 is fine compared to the rest of the industry. TLRY outperforms 68.57% of its industry peers.
Industry RankSector Rank
Current Ratio 2.62
Quick Ratio 1.61
TLRY.CA Yearly Current Assets VS Current LiabilitesTLRY.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 25.41% over the past year.
TLRY shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.23%.
TLRY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 78.86% yearly.
EPS 1Y (TTM)25.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)11.23%
Revenue growth 3Y55.33%
Revenue growth 5Y78.86%
Sales Q2Q%-1.36%

3.2 Future

TLRY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.67% yearly.
The Revenue is expected to grow by 5.68% on average over the next years.
EPS Next Y-222.48%
EPS Next 2Y17.62%
EPS Next 3Y21.07%
EPS Next 5Y18.67%
Revenue Next Year8.45%
Revenue Next 2Y7.11%
Revenue Next 3Y5.97%
Revenue Next 5Y5.68%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
TLRY.CA Yearly Revenue VS EstimatesTLRY.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
TLRY.CA Yearly EPS VS EstimatesTLRY.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TLRY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TLRY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TLRY.CA Price Earnings VS Forward Price EarningsTLRY.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

TLRY's Enterprise Value to EBITDA ratio is in line with the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 17.98
TLRY.CA Per share dataTLRY.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

TLRY's earnings are expected to grow with 21.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.62%
EPS Next 3Y21.07%

More info and screens

0

5. Dividend

5.1 Amount

TLRY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TILRAY BRANDS INC

TSX:TLRY (6/13/2025, 7:00:00 PM)

0.56

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-08 2025-04-08/bmo
Earnings (Next)07-28 2025-07-28/amc
Inst Owners10.08%
Inst Owner ChangeN/A
Ins Owners0.31%
Ins Owner ChangeN/A
Market Cap574.30M
Analysts72.22
Price Target1.8 (221.43%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-140.2%
Min EPS beat(2)-145.1%
Max EPS beat(2)-135.29%
EPS beat(4)0
Avg EPS beat(4)-91.89%
Min EPS beat(4)-145.1%
Max EPS beat(4)-8.93%
EPS beat(8)1
Avg EPS beat(8)-85.68%
EPS beat(12)1
Avg EPS beat(12)-398.32%
EPS beat(16)4
Avg EPS beat(16)-256.75%
Revenue beat(2)0
Avg Revenue beat(2)-8.97%
Min Revenue beat(2)-13.28%
Max Revenue beat(2)-4.66%
Revenue beat(4)0
Avg Revenue beat(4)-7.31%
Min Revenue beat(4)-13.28%
Max Revenue beat(4)-0.75%
Revenue beat(8)1
Avg Revenue beat(8)-2.67%
Revenue beat(12)1
Avg Revenue beat(12)-3.36%
Revenue beat(16)1
Avg Revenue beat(16)-7.96%
PT rev (1m)1.5%
PT rev (3m)-36.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-150%
EPS NY rev (1m)0%
EPS NY rev (3m)-439.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.94%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.51
P/FCF N/A
P/OCF N/A
P/B 0.15
P/tB 0.72
EV/EBITDA 17.98
EPS(TTM)-0.38
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)-0.12
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS1.1
BVpS3.63
TBVpS0.77
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.79%
ROE -34.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 30.88%
FCFM N/A
ROA(3y)-16.09%
ROA(5y)-22.56%
ROE(3y)-20.59%
ROE(5y)-49.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34.12%
GM growth 5Y-3.12%
F-Score4
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA 12.7
Cap/Depr 27.68%
Cap/Sales 4.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.62
Quick Ratio 1.61
Altman-Z -0.81
F-Score4
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)20.35%
Cap/Depr(5y)159.29%
Cap/Sales(3y)4.15%
Cap/Sales(5y)16.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y-222.48%
EPS Next 2Y17.62%
EPS Next 3Y21.07%
EPS Next 5Y18.67%
Revenue 1Y (TTM)11.23%
Revenue growth 3Y55.33%
Revenue growth 5Y78.86%
Sales Q2Q%-1.36%
Revenue Next Year8.45%
Revenue Next 2Y7.11%
Revenue Next 3Y5.97%
Revenue Next 5Y5.68%
EBIT growth 1Y-239.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year133.02%
EBIT Next 3Y37.28%
EBIT Next 5Y23.96%
FCF growth 1Y-24.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.12%
OCF growth 3YN/A
OCF growth 5YN/A